An official website of the United States government
Home
Name
Zykadia
Alternate Names
ceritinib
Abbreviations
None
Category
Chemotherapy
Subcategory
ALK tyrosine kinase inhibitor
NSC Number
None
Primary Site
Lung
Histology
None
Remarks
May 26, 2017: FDA granted regular approval to ceritinib (ZYKADIA) for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test.
April 29, 2014 FDA granted accelerated (breakthrough therapy designation) to ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) with disease progression while on or who are not tolerant to crizotinib.
April 29, 2014 FDA granted accelerated (breakthrough therapy designation) to ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) with disease progression while on or who are not tolerant to crizotinib.
Coding
This drug should be coded
